Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Otsuka Pharmaceutical Acquired iBio's Assets Related To Its Early-stage Programmed Cell Death Protein 1 Agonist Program; iBio Will Receive An Upfront Payment Of $1M And Is Eligible To Receive Additional Contingent Cash Payments Of Up To $52.5M

Author: Benzinga Newsdesk | February 26, 2024 08:48am

Posted In: IBIO